Literature DB >> 21992557

Optical coherence tomographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment.

Pei-Chen Wu1, Chien-Hsiung Lai, Ching-Lung Chen, Chien-Neng Kuo.   

Abstract

PURPOSE: To identify optical coherence tomography (OCT) patterns in diabetic macular edema (DME) that were predictive of visual outcomes after intravitreal bevacizumab (IVB) injection.
METHODS: This was a retrospective study. We examined 31 eyes (24 patients) with clinically significant macular edema that received IVB injections along with macular OCT data. The eyes were categorized into 4 groups by using OCT features: diffuse retinal thickening (DRT), cystoid macular edema (CME), serous retinal detachment (SRD), and vitreomacular interface abnormalities (VMIAs). Changes in retinal thickness, retinal volume, and visual acuity (VA) after IVB injection were compared on the basis of OCT patterns.
RESULTS: After IVB injections, changes in VA logarithm of the minimum angle of resolution were -0.06±0.36, -0.26±0.26, 0.09±0.13, and -0.08±0.15, respectively, for DRT, CME, SRD, and VMIA patterns. Central macular thickness decreased by 70.5±105.5, 110.67±97.28, 181±125.87, and 24.25±77.12 μm for the DRT, CME, SRD, and VMIA patterns, respectively. The CME group was associated with a greater reduction in retinal thickness (P=0.009) and volume (P=0.027) with superior VA improvement (P=0.012) as compared with the DRT, SRD, and VMIA groups.
CONCLUSIONS: Patients with CME gained greater improvement in visual acuity and macular thickness and volume after IVB injection had been administered as the primary treatment for DME, as compared with other patients. The OCT patterns of DME may indicate the appropriate treatment; we consider these patterns to be prognostic of the response to IVB injection for macular edema.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21992557     DOI: 10.1089/jop.2011.0070

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  21 in total

1.  Paired responses to intravitreal bevacizumab in diabetic macular edema: predictors of response in the fellow eye.

Authors:  Peter A Karth; Anne Chang; William Wirostko
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-07-20       Impact factor: 3.117

2.  Efficacy of intravitreal anti-vascular endothelial growth factor or steroid injection in diabetic macular edema according to fluid turbidity in optical coherence tomography.

Authors:  Kyungmin Lee; Heeyoung Chung; Youngsuk Park; Joonhong Sohn
Journal:  Korean J Ophthalmol       Date:  2014-07-22

3.  Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema.

Authors:  Haider R Cheema; Ahmed Al Habash; Essam Al-Askar
Journal:  Int J Ophthalmol       Date:  2014-04-18       Impact factor: 1.779

4.  The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF.

Authors:  C-K Chang; C-K Cheng; C-H Peng
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

5.  Correlation of morphological pattern of optical coherence tomography in diabetic macular edema with systemic risk factors in middle aged males.

Authors:  Sambuddha Ghosh; Preeti Bansal; Harsha Shejao; Raghuraj Hegde; Debesh Roy; Shyamapada Biswas
Journal:  Int Ophthalmol       Date:  2014-03-01       Impact factor: 2.031

6.  Bevacizumab for the management of diabetic macular edema.

Authors:  Francisco Rosa Stefanini; J Fernando Arevalo; Maurício Maia
Journal:  World J Diabetes       Date:  2013-04-15

7.  Reduced effect of anti-vascular endothelial growth factor agents on diabetics with vitreomacular interface abnormalities.

Authors:  Dan Yoon; Irene Rusu; Irene Barbazetto
Journal:  Int Ophthalmol       Date:  2013-11-22       Impact factor: 2.031

8.  Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study.

Authors:  Alexei N Kulikov; Sergei V Sosnovskii; Roman D Berezin; Dmitrii S Maltsev; Dzhambulat H Oskanov; Nikolai A Gribanov
Journal:  Clin Ophthalmol       Date:  2017-11-14

9.  Effect of initial retinal thickness on outcome of intravitreal bevacizumab therapy for diabetic macular edema.

Authors:  Bushra Mushtaq; Niall J Crosby; Antonios T Dimopoulos; Peck Lin Lip; Panagiota Stavrou; Samer El-Sherbiny; Yit Yang
Journal:  Clin Ophthalmol       Date:  2014-04-28

10.  Vitreoretinal interface abnormalities in patients treatedwith ranibizumab for diabetic macular oedema.

Authors:  Yun Wong; David H W Steel; Maged S Habib; Alex Stubbing-Moore; Dalvir Bajwa; Peter J Avery
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-12-12       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.